Parkev Tatevosian, CFA 对 $NVO 的判断变化

频道资料 →频道引用的来源:Barclays analyst Dan Levy、Meta management and CEO Mark Zuckerberg、Nike management共 1 条

Parkev Tatevosian, CFA 自 2026-09-26 起在 1 个视频里谈过 $NVO,最近一次(2026-09-26)为看涨。

2026-09-26看涨
《Novo Nordisk Gives Uninspiring Outlook》
AI 摘要 · 尽管估值与信心有所下调,NVO 仍值得买入,仍有显著上行空间。

诺和诺德向投资者表示,到2030年公司将实现中个位数的收入增长。公司还表示,将把所服务的患者人数从目前的约4650万提升至6000万以上。

Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.

尽管预期强劲,投资者对诺和诺德的表现并不买账。自2026年初以来,该股已下跌超过25%。那么,这一切是否让诺和诺德在股价下跌时成为一个买入机会?

Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?